Division of Musculoskeletal Radiology, Lille University Hospital Center, Centre de Consultations Et D'imagerie de L'appareil Locomoteur, Rue du Professeur Emile Laine, 59037, Lille Cedex, France.
Lille University School of Medicine, Lille, France.
Eur Radiol. 2022 Mar;32(3):1718-1725. doi: 10.1007/s00330-021-08263-4. Epub 2021 Oct 14.
The aim of this study was to assess the feasibility, performance, and complications of a non-surgical, minimally-invasive procedure of deep contraceptive implant removal under continuous ultrasound guidance.
The ultrasound-guided procedure consisted of local anesthesia using lidocaine chlorhydrate 1% (10 mg/mL) with a 21-G needle, followed by hydrodissection using NaCl 0.9% (9 mg/mL) and implant extraction using a Hartmann grasping microforceps. The parameters studied were the implant localization, success and complication rates, pain throughout the intervention, volumes of lidocaïne and NaCl used, duration of the procedure, and size of the incision. Between November 2019 and January 2021, 45 patients were referred to the musculoskeletal radiology department for ultrasound-guided removal of a deep contraceptive implant and were all retrospectively included.
All implants were successfully removed en bloc (100%). The mean incision size was 2.7 ± 0.5 mm. The mean duration of the extraction procedure was 7.7 ± 6.3 min. There were no major complications (infection, nerve, or vessel damage). As a minor complication, 21 patients (46.7%) reported a benign superficial skin ecchymosis at the puncture site, spontaneously regressing in less than 1 week. The procedure was very well-tolerated, with low pain rating throughout (1.0 ± 1.5/10 during implant extraction).
Minimally invasive removal of deep contraceptive implants under continuous ultrasound guidance alone is feasible, effective, and safe. In the present cohort, all implants were successfully removed, whatever the location, with short procedural time, small incision size, low pain levels, and no significant complications. This procedure could become a gold standard in this indication.
• Minimally invasive removal of deep contraceptive implants under continuous ultrasound guidance alone is feasible, which led to a success rate of 100% whatever the location (even close to neurovascular structures), with only a small skin incision (2.7 ± 0.5 mm). • The procedure was safe, quick, without any major complications, and very well tolerated in terms of pain. • This minimally invasive ultrasound-guided procedure could become the future gold standard for the removal of deep contraceptive implants, as an alternative to surgical extraction, even for implants in difficult locations such as subfascial ones or those close to neurovascular structures.
本研究旨在评估在连续超声引导下,采用非手术、微创方法取出深部避孕植入物的可行性、操作性能和并发症。
超声引导下的操作包括使用 1%盐酸利多卡因(10mg/mL)和 21-G 针进行局部麻醉,然后使用 0.9%氯化钠(9mg/mL)进行水分离,最后使用 Hartmann 抓握微夹取出植入物。研究的参数包括植入物的定位、成功率和并发症发生率、整个介入过程中的疼痛程度、利多卡因和氯化钠的使用量、手术持续时间和切口大小。2019 年 11 月至 2021 年 1 月期间,共有 45 名患者因超声引导下取出深部避孕植入物而转至肌肉骨骼放射科,所有患者均进行了回顾性分析。
所有植入物均整块(100%)成功取出。平均切口大小为 2.7±0.5mm。取出手术的平均持续时间为 7.7±6.3min。无重大并发症(感染、神经或血管损伤)。作为一种轻微并发症,21 名患者(46.7%)在穿刺部位出现良性的浅表皮肤瘀斑,不到 1 周内自行消退。该操作耐受性良好,整个过程中疼痛程度较轻(植入物取出时为 1.0±1.5/10)。
在连续超声引导下单独进行深部避孕植入物的微创取出是可行的、有效且安全的。在本队列中,无论植入物位置如何,所有植入物均成功取出,手术时间短,切口小,疼痛程度低,无明显并发症。该操作可能成为该适应证的金标准。
• 单独在连续超声引导下微创取出深部避孕植入物是可行的,无论植入物位置(甚至靠近神经血管结构)如何,成功率均为 100%,切口仅 2.7±0.5mm。• 该操作安全、快速,无任何重大并发症,且疼痛程度低,患者耐受性良好。• 这种微创超声引导下的操作可能成为深部避孕植入物取出的未来金标准,替代手术切除,即使是对于难以触及的植入物,如筋膜下植入物或靠近神经血管结构的植入物。